Expression of urokinase plasminogen activator and plasminogen activator inhibitor type-1 in ovarian cancer and its clinical significance

By          

Oncology Reports, Vol. 29, Iss. 2, 2013-01 ,pp. : 637-645

Spandidos Publications

Access to resources Recommend Favorite

Physiological and pathological changes of plasma urokinase-type plasminogen activator, plasminogen activator inhibitor-1, and urokinase-type plasminogen activator receptor levels in healthy females and breast cancer patients

By Chung Hyun   Rha Sun   Park Joon   Yoo Nae   Kim Joo   Roh Jae   Min Jin   Lee Kyong   Kim Byung   Kim Jin  

Breast Cancer Research and Treatment, Vol. 49, Iss. 1, 1998-05 ,pp. : 41-50

Springer Publishing Company

Access to resources Recommend Favorite

Transforming growth factor-1 promotes the transcriptional activation of plasminogen activator inhibitor type 1 in carcinoma-associated fibroblasts

By              

Molecular Medicine Reports, Vol. 6, Iss. 5, 2012-01 ,pp. : 1001-1005

Spandidos Publications

Access to resources Recommend Favorite

Urokinase plasminogen activator and its inhibitor, PAI-1, in association with progression-free survival in early stage endometrial cancer

By Fredstorp-Lidebring M.   Bendahl P.-O.   Brunner N.   Casslen B.   Hogberg T.   Langstrom-Einarsson E.   Willen R.   Ferno M.  

European Journal of Cancer, Vol. 37, Iss. 18, 2001-12 ,pp. : 2339-2348

Elsevier

Access to resources Recommend Favorite

Clinical Relevance of Urokinase-Type Plasminogen Activator, Its Receptor, and Its Inhibitor Type 1 in Endometrial Cancer

By Tecimer C.   Doering D.L.   Goldsmith L.J.   Meyer J.S.   Abdulhay G.   Wittliff J.L.  

Gynecologic Oncology, Vol. 80, Iss. 1, 2001-01 ,pp. : 48-55

Elsevier

Access to resources Recommend Favorite